Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa

Completed

Conditions: Hemorrhage
Atrial Fibrillation

Interventions: Drug: Dabigatran 75 mg
Drug: Dabigatran 150 mg

First Posted Date: 2014-05-29

Last Posted Date: 2016-04-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 191

Registration Number: NCT02149303

Locations: 🇺🇸
1160.200.01 Boehringer Ingelheim Investigational Site, Brooklyn, New York, United States
🇺🇸
1160.200.05 Boehringer Ingelheim Investigational Site, Stony Brook, New York, United States
🇺🇸
1160.200.06 Boehringer Ingelheim Investigational Site, Boston, Massachusetts, United States

and more 2 locations

Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)

Phase 3

Completed

Conditions: Colorectal Neoplasms

Interventions: Drug: Nintedanib (BIBF 1120)
Drug: Placebo
Drug: BSC

First Posted Date: 2014-05-29

Last Posted Date: 2017-07-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 768

Registration Number: NCT02149108

Locations: 🇵🇹
1199.52.3505 Boehringer Ingelheim Investigational Site, Loures, Portugal
🇧🇪
1199.52.3204 Boehringer Ingelheim Investigational Site, Edegem, Belgium
🇺🇸
1199.52.0108 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States

and more 126 locations

Multiple Rising Oral Doses of BI 691751 in Healthy Male Subjects

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: BI 691751
Drug: Placebo

First Posted Date: 2014-05-28

Last Posted Date: 2016-02-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18

Registration Number: NCT02148107

Locations: 🇩🇪
1334.2.1 Boehringer Ingelheim Investigational Site, Berlin, Germany

Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: Xentuzumab, low dose, every week (qw)
Drug: Xentuzumab, middle dose, qw
Drug: Xentuzumab, high dose, qw

First Posted Date: 2014-05-23

Last Posted Date: 2023-08-02

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 21

Registration Number: NCT02145741

Locations: 🇯🇵
National Cancer Center Hospital East, Chiba, Kashiwa, Japan

Ascertainment of EMR-based Clinical Covariates Among Patients Receiving Oral and Non-insulin Injected Hypoglycemic Therapy

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: linagliptin

First Posted Date: 2014-05-16

Last Posted Date: 2017-02-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 166613

Registration Number: NCT02140645

Locations: 🇺🇸
Boehringer Ingelheim Investigational Site, Boston, Massachusetts, United States

Oral and Non-insulin Injected Hypoglycemic Therapy Utilization Patterns

Completed

Conditions: Diabetes Mellitus, Type 2

First Posted Date: 2014-05-14

Last Posted Date: 2015-10-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 615067

Registration Number: NCT02138097

Locations: 🇺🇸
1218.161.1 Boehringer Ingelheim Investigational Site, Boston, Massachusetts, United States

BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis

Phase 3

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: BI 695501
Drug: US-licensed Humira®

First Posted Date: 2014-05-13

Last Posted Date: 2018-01-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 645

Registration Number: NCT02137226

Locations: 🇺🇸
North MS Medical Clinics, Incorporated, Tupelo, Mississippi, United States
🇺🇸
Glacier View Research Institute, Kalispell, Montana, United States
🇺🇸
Accurate Clinical Research, Inc., Lincoln, Nebraska, United States

and more 128 locations

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 639667

Phase 1

Withdrawn

Conditions: Healthy

Interventions: Drug: BI 639667
Drug: Placebo

First Posted Date: 2014-05-08

Last Posted Date: 2014-07-15

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT02133482

Long-term Observation PMS for Afatinib

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Afatinib dimaleate

First Posted Date: 2014-05-06

Last Posted Date: 2018-09-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1605

Registration Number: NCT02131259

Locations: 🇯🇵
Boehringer Ingelheim Investigational Site 145, Adachi Tokyo, Japan
🇯🇵
Boehringer Ingelheim Investigational Site 47, Akita Akita, Japan
🇯🇵
Boehringer Ingelheim Investigational Site 44, Akita Akita, Japan

and more 429 locations

LUX-Head & Neck 4: Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy

Phase 3

Terminated

Conditions: Head and Neck Neoplasms

Interventions: Drug: Afatinib
Drug: Placebo

First Posted Date: 2014-05-06

Last Posted Date: 2019-03-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT02131155

Locations: 🇨🇳
1200.162.86013 Boehringer Ingelheim Investigational Site, Jinan, China
🇨🇳
1200.162.86007 Boehringer Ingelheim Investigational Site, Chengdu, China
🇰🇷
1200.162.82001 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of

and more 13 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy